Charles River Labs (CRL – Research Report) received a Hold rating and price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $165.35.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Sykes is a 4-star analyst with an average return of 5.3% and a 49.17% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Danaher, Charles River Labs, and Pacific Biosciences.
Charles River Labs has an analyst consensus of Hold, with a price target consensus of $177.62.
CRL market cap is currently $9.05B and has a P/E ratio of 677.89.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRL in relation to earlier this year. Last month, Joseph W LaPlume, the EVP, Corp Strategy & Develop of CRL sold 4,400.00 shares for a total of $715,000.00.
Read More on CRL:
- Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904
- Okta upgraded, Quest Diagnostics downgraded: Wall Street’s top analyst calls
- Charles River upgraded to Neutral from Sell at Citi
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Charles River upgraded to Neutral from Sell at Redburn Atlantic